International Edition
Latest News
Health

Diabetes Cases to Hit 1.3 Billion by 2050: Advances in Care and Access Issues

A 2023 analysis estimates over 1.3 billion people will live with diabetes by 2050. Global diabetes prevalence is projected to reach over 830 million people by 2026, creating an urgent need for expanded access to care and improved…

Diabetes Cases to Hit 1.3 Billion by 2050: Advances in Care and Access Issues

A 2023 analysis estimates over 1.3 billion people will live with diabetes by 2050.

Global diabetes prevalence is projected to reach over 830 million people by 2026, creating an urgent need for expanded access to care and improved treatment options.

As the condition affects more people than ever, researchers point to major scientific progress and growing advocacy for affordable insulin.

The rising global burden is substantial, with a 2023 analysis estimating that more than 1.3 billion people will live with diabetes by 2050. Most of these individuals reside in low- and middle-income countries, where access to essential supplies like insulin remains inconsistent.

“Insulin is not for me, it is for the world,” said Frederick Banting, the Canadian scientist who co-discovered insulin, upon selling the patent for one Canadian dollar in 1923.

Diabetes Cases to Hit 1.3 Billion by 2050: Advances in Care and Access Issues
Photo: theconversation.com

Scientific Advances in Diabetes Care

Researchers are exploring new methods to manage Type 1 diabetes, including transplanting insulin-producing cells grown in laboratories or derived from donors. Clinical trials show many transplant recipients need much less insulin or can stop using it entirely. However, the risk of the immune system rejecting these new cells remains a primary hurdle, as most patients would otherwise require a lifetime of immunosuppressant medication.

Alternative approaches currently under investigation involve modifying cells before implantation to evade immune detection or using targeted therapies to protect insulin-producing cells without compromising the rest of the immune system.

For Type 2 diabetes, which accounts for over 90% of cases, recent clinical data offers further encouragement. A study published in October 2026 involving nearly 100 participants found that more than half achieved remission six months after adopting a supervised low-calorie diet and exercise program.

Early Screening Identifies Type 1 Diabetes Risk Before Symptoms

Because 90% of people diagnosed with Type 1 diabetes do not have a family member with the condition, some experts are calling for broader screening protocols. Currently, blood tests can identify immune markers that signal the body is targeting insulin-producing cells long before clinical symptoms appear.

Region Projected 2050 Prevalence
North Africa and Middle East ~17%
Latin America and Caribbean ~11%

Early intervention with drugs like teplizumab can delay the onset of Type 1 diabetes, potentially providing years of relief from insulin injections and blood sugar monitoring. While programs like TrialNet currently offer screening for those with a family history of the disease, experts in Europe are advocating for universal screening to capture cases that would otherwise go undetected until symptoms emerge.

Addressing Barriers to Treatment

Despite these medical breakthroughs, global inequality in healthcare access persists. Researchers estimate that more than 250 million people worldwide are currently unaware they have Type 2 diabetes, preventing them from accessing early treatment.

Cost remains a critical barrier for those who are diagnosed. Only about 1 in 2 people across the globe with Type 2 diabetes have access to the insulin they need. GLP-1 access is concentrated in high-income countries, and costs can be prohibitive. Researchers are now working to simplify how insulin is made and distributed to close the gap between scientific discovery and patient access.

About the author: Health Desk

Health Desk at Archynewsy.